Description
Snovitra 40 Mg Tablets — High-Dose Vardenafil for Erectile Dysfunction
Snovitra 40 Mg Tablets contain 40 mg of vardenafil hydrochloride, a selective phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) in adult men. Vardenafil 40 mg represents a higher dose than the standard vardenafil tablet strengths (5 mg, 10 mg, 20 mg) available in many markets, and is intended for men who require more robust PDE5 inhibition for adequate erectile response. Snovitra 40 Mg must be prescribed by a qualified medical practitioner who can assess the appropriateness of this dose for the individual patient.
Vardenafil and PDE5 Inhibition: Mechanism of Action
Penile erection depends on the relaxation of smooth muscle in the corpus cavernosum and penile arteries — a process initiated by sexual stimulation and mediated by the nitric oxide (NO)–cyclic GMP (cGMP) signalling pathway. Sexual stimulation activates non-adrenergic non-cholinergic (NANC) nerve fibres and vascular endothelium in the corpus cavernosum, triggering the release of nitric oxide. NO diffuses into smooth muscle cells and activates guanylate cyclase, which converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Elevated cGMP activates protein kinase G, reducing intracellular free calcium concentrations and causing smooth muscle relaxation. The resulting vasodilation increases arterial inflow into the lacunar spaces of the corpus cavernosum and compresses penile venous drainage, producing erection.
Phosphodiesterase type 5 (PDE5) hydrolyses and inactivates cGMP, limiting the duration and magnitude of smooth muscle relaxation. Vardenafil competitively and selectively inhibits PDE5 at a non-catalytic binding site, increasing cGMP bioavailability and amplifying the pro-erectile response to sexual stimulation. Because the entire mechanism is permissive and dependent on NO release from sexual stimulation, vardenafil does not produce erections independently of arousal.
Pharmacological Profile of Vardenafil
Potency and Selectivity
Vardenafil is one of the most potent PDE5 inhibitors in clinical use, with an IC50 for PDE5 of approximately 0.1 nM — approximately 10-fold more potent than sildenafil and comparable to tadalafil. Its selectivity for PDE5 versus PDE6 (retinal photoreceptors, responsible for colour vision side effects of sildenafil) is approximately 15-fold, contributing to a lower incidence of visual adverse effects than sildenafil. It is also highly selective for PDE5 versus PDE1, PDE2, PDE3, PDE4, and PDE11.
Pharmacokinetics
Vardenafil is absorbed rapidly after oral administration, with Tmax typically 30–120 minutes after dosing. Absolute bioavailability is approximately 15%, reflecting significant first-pass hepatic metabolism, primarily via CYP3A4 with minor CYP3A5 and CYP2C9 contributions. The active metabolite M1 (N-desethylvardenafil) has approximately 28% the in vitro PDE5 inhibitory potency of the parent compound and accounts for approximately 7% of total systemic exposure. The terminal plasma half-life of vardenafil is approximately 4–5 hours. High-fat meals reduce Cmax by approximately 36% and delay Tmax by 1 hour, without affecting overall exposure (AUC); light meals do not affect pharmacokinetics significantly.
The 40 Mg Dose
Standard vardenafil dosing for ED begins at 10 mg for most treatment-naive patients, with dose titration to 20 mg if the lower dose is well tolerated but insufficiently effective, or down to 5 mg if adverse effects are problematic. The 40 mg dose used in Snovitra 40 Mg exceeds the standard maximum dose of 20 mg typically recommended in regulatory labelling. This higher dose is intended for men with more severe or treatment-refractory ED, or for whom lower doses have produced suboptimal erectile responses. The prescribing physician must weigh the potential for increased efficacy against the increased likelihood and severity of dose-dependent adverse effects at 40 mg.
Dosage and Administration
Snovitra 40 Mg should be taken as directed by the prescribing physician — typically approximately 25–60 minutes before anticipated sexual activity. The tablet should be swallowed whole with water. No more than one dose should be taken within any 24-hour period. The 40 mg dose is not appropriate for all patients; it requires individual clinical assessment. Dose reduction may be required in elderly patients, those with moderate hepatic impairment, and those receiving CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, HIV protease inhibitors), which can markedly increase vardenafil plasma concentrations.
Drug Interactions
Clinically significant interactions include: potent CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) — dose reductions of vardenafil are necessary; alpha-blockers (doxazosin, tamsulosin) — combination can cause symptomatic hypotension, requiring careful dose management and clinical monitoring; antihypertensive agents — additive blood pressure lowering. Vardenafil prolongs the QTc interval slightly; it should not be combined with class IA antiarrhythmics (quinidine, procainamide) or class III antiarrhythmics (amiodarone, sotalol).
Contraindications
Snovitra 40 Mg is contraindicated with organic nitrates in any formulation and any frequency of administration, due to the risk of profound hypotension. It is contraindicated in patients for whom sexual activity carries unacceptable cardiovascular risk, in those with severe hepatic impairment, and in patients with rare hereditary retinal conditions such as retinitis pigmentosa. It is also contraindicated in patients with a history of NAION associated with PDE5 inhibitor use.
Adverse Effects
Common adverse effects include headache, flushing, nasal congestion, dyspepsia, and dizziness, all consistent with the vasodilatory class effects of PDE5 inhibition. Adverse effects are dose-dependent and are likely to be more frequent at 40 mg than at standard doses. Rare serious adverse events include non-arteritic anterior ischaemic optic neuropathy (NAION), sudden sensorineural hearing loss, and priapism — erection lasting more than 4 hours requiring immediate emergency urological attention.
Important Notes
Snovitra 40 Mg is a prescription-only medication for use in adult men only. The higher-than-standard dose requires careful medical supervision and regular clinical review. It does not protect against sexually transmitted infections.
Storage
Store Snovitra 40 Mg Tablets below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
References
- National Library of Medicine — DailyMed: Vardenafil prescribing information
- MedlinePlus (U.S. National Library of Medicine): Vardenafil — MedlinePlus Drug Information
- National Center for Biotechnology Information — PubMed: Hellstrom WJ et al. “Vardenafil for treatment of men with erectile dysfunction.” J Androl. 2002;23(6):763–71.
- Mayo Clinic: Vardenafil (Oral Route) — Mayo Clinic
- UK Electronic Medicines Compendium (EMC): Levitra 10 mg film-coated tablets — Summary of Product Characteristics. Bayer plc.


Reviews
There are no reviews yet.